{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:17:28Z","timestamp":1784200648777,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Optimum Patient Care Global Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"DOI":"10.1007\/s11882-026-01264-7","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:09:15Z","timestamp":1773904155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Severe Asthma Patients\u2019 Characteristics in Mexico Versus International Severe Asthma Registry (ISAR) Global"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5713-5331","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"Larenas-Linnemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7193-9582","authenticated-orcid":false,"given":"Saraid","family":"Cerda-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3073-6604","authenticated-orcid":false,"given":"Nidia K.","family":"Castill\u00f3n-Benavides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-8770","authenticated-orcid":false,"given":"Elvia Angelica","family":"Contreras-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2622-1536","authenticated-orcid":false,"given":"Ulises N.","family":"Garc\u00eda-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1889-5826","authenticated-orcid":false,"given":"Lilia M.","family":"Borboa-Olivares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6765-5074","authenticated-orcid":false,"given":"Nadia","family":"Aguilar-Hinojosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2620-0735","authenticated-orcid":false,"given":"Karen L.","family":"Rivera-Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5977-3230","authenticated-orcid":false,"given":"Itzel V.","family":"Ochoa-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5656-5196","authenticated-orcid":false,"given":"Mar\u00eda de la Luz","family":"Garc\u00eda-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6786-7247","authenticated-orcid":false,"given":"Ricardo","family":"Campos-Cerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7880-7096","authenticated-orcid":false,"given":"Claudine I.","family":"Nava-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5707-0240","authenticated-orcid":false,"given":"Yair H.","family":"Gonz\u00e1lez-Tuyub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-7108","authenticated-orcid":false,"given":"Victor","family":"Gonz\u00e1lez-Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8250-1129","authenticated-orcid":false,"given":"Hugo A.","family":"Azuara-Trujillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2311-4751","authenticated-orcid":false,"given":"Claudia Elizabeth","family":"Jim\u00e9nez-Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9876-3206","authenticated-orcid":false,"given":"Elsy M.","family":"Navarrete-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6441-8869","authenticated-orcid":false,"given":"Blanca E.","family":"Del R\u00edo-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0167-5034","authenticated-orcid":false,"given":"Laura D.","family":"Mendoza-Reyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5255-2259","authenticated-orcid":false,"given":"Dominic A.","family":"Friston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2692-8507","authenticated-orcid":false,"given":"Ghislaine","family":"Scelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-9992","authenticated-orcid":false,"given":"David B.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"1264_CR1","doi-asserted-by":"crossref","unstructured":"The Global Asthma Report 2022. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2022;26(Supp 1):1-104.","DOI":"10.5588\/ijtld.22.1010"},{"key":"1264_CR2","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. 2025. Available from: https:\/\/ginasthma.org\/reports\/."},{"key":"1264_CR3","doi-asserted-by":"crossref","unstructured":"Pembrey L, Brooks C, Mpairwe H, Figueiredo CA, Oviedo AY, Chico M, et al. Asthma inflammatory phenotypes on four continents: most asthma is non-eosinophilic. Int J Epidemiol. 2023;52(2):611-23.","DOI":"10.1093\/ije\/dyac173"},{"key":"1264_CR4","doi-asserted-by":"crossref","unstructured":"Bateman ED, Price DB, Wang HC, Khattab A, Schonffeldt P, Catanzariti A, et al. Short-acting beta(2)-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J. 2022;59(5).","DOI":"10.1183\/13993003.01402-2021"},{"key":"1264_CR5","doi-asserted-by":"crossref","unstructured":"Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, et al. Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry. Chest. 2020;157(4):790-804.","DOI":"10.1016\/j.chest.2019.10.053"},{"key":"1264_CR6","doi-asserted-by":"crossref","unstructured":"Neffen H, Moraes F, Viana K, Di Boscio V, Levy G, Vieira C, et al. Asthma severity in four countries of Latin America. BMC Pulm Med. 2019;19(1):123.","DOI":"10.1186\/s12890-019-0871-1"},{"key":"1264_CR7","doi-asserted-by":"crossref","unstructured":"Bulathsinhala L, Eleangovan N, Heaney LG, Menzies-Gow A, Gibson PG, Peters M, et al. Development of the international severe asthma registry (ISAR): A Modified Delphi Study. J Allergy Clin Immunol Pract. 2019;7(2):578-88 e2.","DOI":"10.1016\/j.jaip.2018.08.016"},{"key":"1264_CR8","doi-asserted-by":"crossref","unstructured":"Larenas-Linnemann D, Rhee CK, Altraja A, Busby J, Tran TN, Wang E, et al. International severe asthma registry (ISAR): 2017-2024 status and progress update. Tuberc Respir Dis (Seoul). 2025; 88(2):193-215.","DOI":"10.4046\/trd.2024.0198"},{"key":"1264_CR9","doi-asserted-by":"crossref","unstructured":"Carrillo G, Mendez-Dominguez N, Datta-Banik R, Figueroa-Lopez F, Estrella-Chan B, Alvarez-Baeza A, et al. Asthma mortality and hospitalizations in Mexico from 2010 to 2018: Retrospective epidemiologic profile. Int J Environ Res Public Health. 2020;17(14).","DOI":"10.3390\/ijerph17145071"},{"key":"1264_CR10","unstructured":"Consejo Nacional de Poblaci\u00f3n C. Proyecciones de la Poblaci\u00f3n de M\u00e9xico y de las Entidades Federativas, 2020\u20132070. 2024. Available from: https:\/\/www.gob.mx\/conapo."},{"key":"1264_CR11","unstructured":"United States Census Bureau. U.S. and world population clock. 2025. Available from: https:\/\/www.census.gov\/popclock."},{"key":"1264_CR12","doi-asserted-by":"crossref","unstructured":"Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007;30(3):452-6.","DOI":"10.1183\/09031936.00165106"},{"key":"1264_CR13","doi-asserted-by":"crossref","unstructured":"Calhoun WJ, Haselkorn T, Miller DP, Omachi TA. Asthma exacerbations and lung function in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2015;136(4):1125-7 e4.","DOI":"10.1016\/j.jaci.2015.05.014"},{"key":"1264_CR14","doi-asserted-by":"crossref","unstructured":"Ortega H, Yancey SW, Keene ON, Gunsoy NB, Albers FC, Howarth PH. Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2018;6(3):980-6 e1.","DOI":"10.1016\/j.jaip.2017.12.019"},{"key":"1264_CR15","doi-asserted-by":"crossref","unstructured":"Meulmeester FL, Mailhot-Larouche S, Celis-Preciado C, Lemaire-Paquette S, Ramakrishnan S, Wechsler ME, et al. Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respir Med. 2025.","DOI":"10.1016\/S2213-2600(25)00037-2"},{"key":"1264_CR16","doi-asserted-by":"crossref","unstructured":"Yadav CP, Chakraborty A, Price DB, Mien Lim LH, Juang YR, Beasley R, et al. Prediction pathway for severe asthma exacerbations: a Bayesian Network analysis. Chest. 2025.","DOI":"10.1016\/j.chest.2025.04.046"},{"key":"1264_CR17","doi-asserted-by":"crossref","unstructured":"Gyawali B, Georas SN, Khurana S. Biologics in severe asthma: a state-of-the-art review. Eur Respir Rev. 2025;34(175).","DOI":"10.1183\/16000617.0088-2024"},{"key":"1264_CR18","unstructured":"Scelo G, Tran TN, Le TT, Faregas M, Dorscheid D, Busby J, et al. Exploring definitions and predictors of response to biologics for severe asthma. J Allergy Clin Immunol Pract. 2024."},{"key":"1264_CR19","doi-asserted-by":"crossref","unstructured":"Pavord ID, Christenson S, Panettieri RA, Jr. Disease modification in severe asthma-are we there yet? J Allergy Clin Immunol Pract. 2025;13(7):1574-80.","DOI":"10.1016\/j.jaip.2025.05.019"},{"key":"1264_CR20","doi-asserted-by":"crossref","unstructured":"Couillard S, Pavord I, Hoyte F, Siddiqui S, Martin N, Menzies-Gow A, et al. \"Treat-to-target\": A call for earlier targeted intervention in asthma. J Allergy Clin Immunol Pract. 2025;13(7):1553-8.","DOI":"10.1016\/j.jaip.2025.05.012"},{"key":"1264_CR21","doi-asserted-by":"crossref","unstructured":"Larenas-Linnemann D, Castro M. New advances in asthma care: Improving management and outcomes. J Allergy Clin Immunol Pract. 2025;13(7):1605-8.","DOI":"10.1016\/j.jaip.2025.05.030"},{"key":"1264_CR22","doi-asserted-by":"crossref","unstructured":"Porsbjerg CM, Townend J, Bergeron C, Christoff GC, Katsoulotos GP, Larenas-Linnemann D, et al. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma. Front Immunol. 2024;15:1361891.","DOI":"10.3389\/fimmu.2024.1361891"},{"key":"1264_CR23","doi-asserted-by":"crossref","unstructured":"Canonica GW, Blasi F, Carpagnano GE, Guida G, Heffler E, Paggiaro P, et al. Severe asthma network Italy definition of clinical remission in severe asthma: A delphi consensus. J Allergy Clin Immunol Pract. 2023;11(12):3629-37.","DOI":"10.1016\/j.jaip.2023.07.041"},{"key":"1264_CR24","doi-asserted-by":"crossref","unstructured":"Canonica GW, Blasi F, Paggiaro P, Heffler E, Braido F, Brussino L, et al. Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI). World Allergy Organ J. 2025;18(1):101016.","DOI":"10.1016\/j.waojou.2024.101016"},{"key":"1264_CR25","doi-asserted-by":"crossref","unstructured":"Perez-de-Llano L, Scelo G, Tran TN, Le TT, Fageras M, Cosio BG, et al. Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults. Am J Respir Crit Care Med. 2024;210(7):869-80.","DOI":"10.1164\/rccm.202311-2192OC"},{"key":"1264_CR26","doi-asserted-by":"crossref","unstructured":"Thomson NC, Polosa R, Sin DD. Cigarette smoking and asthma. J Allergy Clin Immunol Pract. 2022;10(11):2783-97.","DOI":"10.1016\/j.jaip.2022.04.034"},{"key":"1264_CR27","doi-asserted-by":"crossref","unstructured":"Lee KI, Han Y, Ryu JS, In SM, Kim JY, Park JS, et al. Tobacco smoking could accentuate epithelial-mesenchymal transition and Th2-type response in patients with chronic rhinosinusitis with nasal polyps. Immune Netw. 2022;22(4):e35.","DOI":"10.4110\/in.2022.22.e35"},{"key":"1264_CR28","doi-asserted-by":"crossref","unstructured":"Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. Expert Rev Clin Immunol. 2017;13(1):15-26.","DOI":"10.1080\/1744666X.2016.1212660"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01264-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-026-01264-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01264-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:09:23Z","timestamp":1773904163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-026-01264-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1264"],"URL":"https:\/\/doi.org\/10.1007\/s11882-026-01264-7","relation":{},"ISSN":["1534-6315"],"issn-type":[{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported human data collection, performed by the authors, was in accordance with the ethical standards of the institutional and\/or national research committees of the countries participating in ISAR and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement"}},{"value":"The data of this study was provided by the Observational and Pragmatic Research Institute (OPRI) Pte Ltd. This study was funded by Optimum Patient Care Global Ltd (OPCG).\u00a0The International Severe Asthma Registry (ISAR) is operated by OPCG and co-funded by OPCG and\u00a0AstraZeneca Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financing"}},{"value":"D\u00e9sir\u00e9e Larenas-Linnemann reports personal fees from ALK-Abell\u00f3, AstraZeneca national and global, Bayer, Bioderma, Chiesi, Grunenthal, Grin, GlaxoSmithKline national and global, Viatris, Novartis, Pfizer, Sanofi, Siegfried, Syneos Health, Carnot, grants for guideline development from Abbvie, Bayer, Chiesi, Lilly, Sanofi, AstraZeneca, Pfizer, Novartis, Circassia, UCB, GlaxoSmithKline, outside the submitted work. Saraid Cerda Reyes declares receiving conference fees from Novartis S.A de C.V, GlaxoSmithKline Mexico, AstraZeneca Mexico and, Sanofi Mexico. Nidia K. Castillon Benavides declares no relevant conflict of interest. Elvia Angelica Contreras Contreras declares no relevant conflict of Interest. Ulises N. Garc\u00eda-Ram\u00edrez received fees as speaker and advisory board from: AstraZeneca, GlaxoSmithKline, Sanofi Genzyme, Chiesi and Novartis. Lilia M. Borboa Olivares received congress support from AstraZeneca, and Octapharma. Nadia Aguilar-Hinojosa received speaker\u2019s fees and congress support from AstraZeneca Mexico. Karen L. Rivera Alvarado declares no relevant conflict of interest. Itzel V. Ochoa-Garc\u00eda was a speaker for AstraZeneca. Maria de la luz Garcia participated in advisory boards by Carnot and received speaker\u2019s fees by Armstrong, Siegfried, and Chiesi. Ricardo Campos Cerda declares no relevant conflict of interest. Claudine I. Nava Ram\u00edrez declares receiving conference fees from Novartis S.A. de C.V. Yair H Gonz\u00e1lez Tuyub received fees as a speaker and advisory board member from: AstraZeneca, GlaxoSmithKline, and IPI-Asacpharma. V\u00edctor Gonz\u00e1lez-Uribe reports receiving honoraria for lectures, consultancy fees, advisory boards, and research grants from the following companies: GlaxoSmithKline, Sanofi, AstraZeneca, FAES Farma, ALK, and AbbVie. Hugo A. Azuara-Trujillo has received speaker and consultant fees for Astra Zeneca, GlaxoSmithKline, Takeda, and Novartis. Claudia E. Jimenez declares no relevant conflict of interest. Elsy M. Navarrete- Rodr\u00edguez reports receiving honoraria for lectures, consultancy fees, advisory boards, from the following companies: GlaxoSmithKline, Sanofi, AstraZeneca, AbbVie, Lilly, and Armstrong. Blanca E. del-Rio-Navarro reports receiving honoraria for lectures, consultancy fees, advisory boards, and research grants from the following companies: OPELLA, Sanofi, and AstraZeneca. Laura Mendoza-Reyna has received speaker and consultant fees from GlaxoSmithKline, Pfizer, and Sanofi. Dominic (A) Friston is an employee of Optimum Patient Care (OPC). OPC is a co-founder of the International Severe Asthma Registry. Ghislaine Scelo is a consultant for Observational and Pragmatic Research Institute (OPRI). OPRI conducted this study in collaboration with Optimum Patient Care, a co-founder of the International Severe Asthma Registry. David (B) Price has advisory board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris, Teva Pharmaceuticals; consultancy agreements with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris, Teva Pharmaceuticals; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Chiesi, Viatris, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, and UK National Health Service; payment for lectures\/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Inside Practice, GlaxoSmithKline, Medscape, Viatris, Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme, Teva Pharmaceuticals; payment for travel\/accommodation\/meeting expenses from AstraZeneca, Boehringer Ingelheim, Novartis, Medscape, Teva Pharmaceuticals.; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); is peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation Programme, and Health Technology Assessment; and he was an expert witness for GlaxoSmithKline.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}